New tumor markers for testicular cancer - in the here and now and in the future

• Published in: Aktuelle Urologie Vol. 55; no. 6; p. 520
• Main Authors: Schoch, Justine, Schmelz, Hans, Dieckmann, Klaus-Peter, Nestler, Tim
• Format: Journal Article
• Language: German
• Published: Germany 01.12.2024
• Subjects: Biomarkers, Tumor - blood; Biomarkers, Tumor - genetics; Humans; Male; MicroRNAs - blood; MicroRNAs - genetics; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal - blood; Neoplasms, Germ Cell and Embryonal - diagnosis; Neoplasms, Germ Cell and Embryonal - genetics; Neoplasms, Germ Cell and Embryonal - pathology; Neoplasms, Germ Cell and Embryonal - therapy; Neoplastic Cells, Circulating - pathology; Testicular Neoplasms - blood; Testicular Neoplasms - diagnosis; Testicular Neoplasms - genetics; Testicular Neoplasms - pathology; Testicular Neoplasms - therapy
• ISSN: 1438-8820
• DOI: 10.1055/a-2422-0354

Germ cell tumors of the testis are the most common tumor entities in young men. Since the introduction of platinum-based chemotherapy in the 1970s, most patients can be cured despite the aggressiveness of germ cell tumors. Optimal serum tumor markers are required for diagnostics, therapy monitoring and aftercare, and these are subject to high requirements. The conventional testicular tumor markers human chorionic gonadotropin (hCG), alpha fetoprotein (AFP) and lactate dehydrogenase (LDH) only meet these requirements with insufficient sensitivity (30-70%). The markers investigated in recent decades, such as PLAP, CEA and NSE, have not become established. Currently, miRNA-371 is being researched in particular. Reliable findings are available for initial staging with significantly better specificities of miRNA-371 compared to conventional tumor markers. Further prospective studies are being conducted for other possible clinical applications, such as follow-up care, therapy monitoring or residual tumors, in order to investigate the revolutionary potential of miRNA-371 in these areas as well. Research is also currently being conducted on circulating tumor cells (CTCs) and cell-free DNA (cfNA) in various areas of application. With regard to germ cell tumors of the testis, however, these analyses are still in their infancy, but it is hoped that this will provide a further sufficient opportunity to use serum tumor markers.